What is the recommended dosing for hydroxyzine (an antihistamine) for anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydroxyzine Dosing for Anxiety

For generalized anxiety disorder in adults, the recommended dose is 50-100 mg four times daily (QID), as specified by the FDA label, though starting at 50 mg daily and titrating based on response is a practical approach supported by clinical trial evidence. 1

Standard Dosing Regimens

Adults with Generalized Anxiety Disorder

  • FDA-approved dosing: 50-100 mg four times daily (QID) for symptomatic relief of anxiety and tension associated with psychoneurosis 1
  • Evidence-based alternative: 50 mg once daily has demonstrated efficacy in multiple controlled trials, with significant anxiolytic effects beginning within the first week of treatment 2, 3
  • Onset of action: 15-30 minutes after oral administration, with effects lasting 4-6 hours 4, 5

Special Populations

Elderly patients or those sensitive to sedation:

  • Start with 25 mg daily and titrate cautiously 4, 5
  • Elderly patients are particularly susceptible to anticholinergic effects and sedation 6
  • Dose should be halved in moderate renal impairment 6

Patients with comorbid insomnia:

  • Bedtime dosing of 50-100 mg provides dual benefits for anxiety and sleep disturbance 4, 5
  • The sedative properties make hydroxyzine particularly useful when both conditions coexist 4

Pediatric dosing (per FDA label):

  • Children under 6 years: 50 mg daily in divided doses 1
  • Children over 6 years: 50-100 mg daily in divided doses 1

Clinical Considerations

Efficacy Profile

  • Hydroxyzine demonstrates superiority over placebo on all anxiety measures from week 1, with particular effectiveness on cognitive components of anxiety 7, 2
  • A 3-month trial showed mean HAM-A score reduction of 12.16 points versus 9.64 for placebo (p=0.019) 3
  • Efficacy is maintained throughout treatment and after abrupt discontinuation without rebound anxiety or withdrawal symptoms 2, 3

Advantages Over Benzodiazepines

  • No dependency or withdrawal issues, unlike benzodiazepines 7
  • Comparable efficacy to bromazepam (6 mg/day) in 3-month trials 3
  • May provide better control of somatic anxiety symptoms (trembling, physical tension) due to anticholinergic effects 4, 5

Common Side Effects

  • Drowsiness/sleepiness is the most common side effect (28% vs 14% placebo), typically appearing in the first week and progressively diminishing 2
  • Other effects include dry mouth (14%), weight gain (12%), and loss of concentration (9%) 2
  • Drowsiness is more frequent at 50 mg compared to 25 mg dosing 8

Critical Contraindications and Precautions

Absolute contraindications:

  • Early pregnancy (specifically contraindicated per UK manufacturer guidelines) 6
  • Closed-angle glaucoma 4, 5
  • Prostatic hypertrophy 4, 5
  • Severe liver disease (may precipitate coma) 6
  • Severe renal impairment (creatinine clearance <10 mL/min) 6

Use with extreme caution in:

  • Elderly patients due to anticholinergic burden 6, 4, 5
  • Patients with cognitive impairment 5
  • Hepatic impairment (avoid in severe cases) 6

Practical Dosing Algorithm

  1. Initial assessment: Verify no contraindications (pregnancy, glaucoma, severe hepatic/renal disease) 6, 4, 5

  2. Starting dose selection:

    • Standard adults: 50 mg once daily or 50 mg QID per FDA label 1, 2
    • Elderly/sensitive patients: 25 mg once daily 4, 5
    • Comorbid insomnia: 50-100 mg at bedtime 4, 5
  3. Titration: Adjust dose according to patient response after 1 week, as anxiolytic effects should be evident by this time 2, 3

  4. Maintenance: Continue effective dose for duration needed; studies support safe use up to 3 months 3

  5. Discontinuation: Can be stopped abruptly without tapering, as no withdrawal syndrome or rebound anxiety occurs 2, 3

Important Clinical Pitfalls

  • Do not use as monotherapy for major depressive disorder—hydroxyzine does not constitute adequate treatment for comorbid depression 4
  • Monitor for paradoxical agitation, particularly in younger patients, though this is rare 4
  • Avoid concurrent use with other anticholinergic medications in elderly patients to prevent cumulative anticholinergic burden 6
  • Transient drowsiness in week 1 is expected and typically resolves—counsel patients accordingly to improve adherence 2

References

Guideline

Hydroxyzine Dosing and Effectiveness for Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hydroxyzine for Anxiety and Panic Attacks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recent clinical trials of hydroxyzine in generalized anxiety disorder.

Acta psychiatrica Scandinavica. Supplementum, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.